Edesa Biotech prices USD 25 million follow-on offering at USD 5.5 per unit

Closing is expected about Aug. 21, 2026.

Edesa Biotech priced a USD 25 million underwritten public offering of common shares, pre-funded warrants and common share warrants.

• The deal includes 3,870,500 common shares with matching common share warrants, priced at USD 5.5 per share-warrant package.
• It also offers pre-funded warrants for up to 675,000 shares with matching common share warrants, priced at USD 5.4999 per package.
• Common share warrants carry a USD 7.5 exercise price and expire in 18 months or 30 days after Phase 2 EB06 vitiligo topline data, whichever is earlier.
• Underwriters received a 30-day option for 681,825 additional shares with matching common share warrants.